Sava Infond’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.6M Buy
18,840
+9,730
+107% +$9.94M 1.6% 18
2026
Q1
$8.38M Sell
9,110
-240
-3% -$243K 1.19% 18
2025
Q4
$10M Sell
9,350
-110
-1% -$105K 1.36% 17
2025
Q3
$7.22M Sell
9,460
-100
-1% -$74.4K 1.02% 20
2025
Q2
$7.45M Sell
9,560
-90
-0.9% -$69.9K 1.16% 19
2025
Q1
$7.97M Buy
9,650
+40
+0.4% +$33.3K 1.52% 15
2024
Q4
$7.42M Buy
+9,610
New +$7.96M 1.31% 17

Other funds holding LLY

Sava Infond's LLY Position: Q2 2026 in Review

Sava Infond increased its Eli Lilly (LLY) stake by 107% in Q2 2026, buying an estimated $9.94M and bringing the position to 18,840 shares worth $22.6M. The position accounts for 1.6% of the portfolio, ranked #18.

Sava Infond first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,600 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Sava Infond held 18,840 shares of Eli Lilly worth $22.6M as of Q2 2026.
  • Sava Infond bought 9,730 Eli Lilly shares in Q2 2026, an estimated $9.94M.
  • Eli Lilly made up 1.6% of Sava Infond's portfolio in Q2 2026, its #18 holding.
  • Sava Infond first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,600 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Sava Infond's 13F filing for Q2 2026, filed 16 Jul 2026.